USPTO Art Unit 1614 Prosecution Statistics

Art Unit Information

Art Unit: 1614
Group: 1610
Tech Center: 1600
Total Cases: 7,749
Last Active: December 2024

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
18975647Herbicidal compositions comprising 2,4-DDecember 2024June 2025Allow610YesNo
18948050CRYSTALLINE FORM OF TRIETHYLENETETRAMINE TETRAHYDROCHLORIDE AND ITS PHARMACEUTICAL USENovember 2024March 2025Allow410NoNo
18928649OPIOID FORMULATIONSOctober 2024March 2025Allow410NoNo
18923620ANTI-AGING PREPARATION FOR SKIN AND APPLICATION THEREOFOctober 2024January 2025Allow310NoNo
18823274PHARMACEUTICAL COMPOSITIONSeptember 2024April 2025Allow710NoNo
18823257PHARMACEUTICAL COMPOSITIONSeptember 2024March 2025Allow610NoNo
18788060NANO-DELIVERY CARRIER FOR TARGETED TUMOR ADMINISTRATION AND APPLICATION THEREOFJuly 2024November 2024Allow300NoNo
18739646Safe Flavoring Composition to Improve Compliance in Colon Cleansing CompositionsJune 2024March 2025Abandon910NoNo
18732203COMPOSITIONS FOR TREATMENT OF DISCOGENIC PAIN, AND PROCESSES FOR MAKING AND USING THE SAMEJune 2024December 2024Allow710YesNo
18672876TRACE ELEMENT COMPOSITIONS, METHODS OF MAKING AND USEMay 2024September 2024Allow300NoNo
18669214LIPIDS AND LIPID NANOPARTICLE FORMULATIONSMay 2024October 2024Allow501NoNo
18668526METHOD TO SELECTIVELY PRODUCE BENZALANILINE FROM A SCHIFF-BASE REACTION INVOLVING ANILINE AND BENZALDEHYDEMay 2024February 2025Allow920NoNo
18665612IMMUNOMODULATING TREATMENTS OF BODY CAVITIESMay 2024December 2024Allow810YesNo
18663349LISINOPRIL FORMULATIONSMay 2024October 2024Allow510YesNo
18653608TRACE ELEMENT COMPOSITIONS, METHODS OF MAKING AND USEMay 2024October 2024Allow510NoNo
18648426TREATMENT OF NEUROFIBROMATOSIS TYPE 1 (NF1) ASSOCIATED PLEXIFORM NEUROFIBROMAS (PN) IN PEDIATRIC PATIENTS WITH MIRDAMETINIBApril 2024March 2025Allow1020NoNo
18647511METHODS AND COMPOSITIONS FOR TREATING CANCERApril 2024April 2025Allow1220YesNo
18639758KAVA COMPOSITIONS AND METHODS OF USEApril 2024May 2025Abandon1320NoNo
18637083INDOLE AND BENZIMIDAZOLE DERIVATIVES AS DUAL 5-HT 2A AND 5-HT6 RECEPTOR ANTAGONISTSApril 2024April 2025Allow1210NoNo
18624670TREATMENTS WITH NIROGACESTATApril 2024October 2024Allow620NoNo
18618110SUBSTITUTED NAPHTHYL P38ALPHA MITOGEN-ACTIVATED PROTEIN KINASE INHIBITORSMarch 2024February 2025Allow1121NoNo
18609128DRIED NANOPARTICLE COMPOSITIONSMarch 2024October 2024Allow710NoNo
18587175ORAL GLIPTIN COMPOSITIONS AND METHOD FOR PREPARATION THEREOFFebruary 2024January 2025Allow1111NoNo
18583696METHODS AND POLYMER COMPOSITIONS FOR TREATING RETINAL DETACHMENT AND OTHER OCULAR DISORDERSFebruary 2024January 2025Abandon1110NoNo
18581307SPLICING MODULATOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USEFebruary 2024April 2025Allow1411NoNo
18443875HYDROCORTISONE ORAL LIQUID FORMULATIONSFebruary 2024December 2024Abandon1001NoNo
18441413MAGNESIUM BIOTINATE COMPOSITIONS AND METHODS OF USEFebruary 2024February 2025Allow1201NoNo
18439677FABRICATION OF NOVEL NANO-SIZED [4{3,4-BIS-[(5-BROMO-2-HYDROXY-BENZYLIDENE)-AMINO]-PHENYL}-PHENYL-METHANONE] RU(III) COMPLEX FOR PHARMACEUTICAL APPLICATIONSFebruary 2024August 2024Allow610NoNo
18417750COMPOSITIONS COMPRISING AN UROLITHIN COMPOUNDJanuary 2024January 2025Allow1210NoNo
18414185TREATMENTS WITH NIROGACESTATJanuary 2024August 2024Allow710NoNo
18405670EYE DROP COMPOSITIONJanuary 2024November 2024Allow1010NoNo
18543199SOLID SUBSTRATES FOR PROMOTING CELL AND TISSUE GROWTHDecember 2023June 2025Allow1810NoNo
18538562METHODS OF INACTIVATION OF VIRUSES USING N-METHYLGLUCAMIDE AND ITS DERIVATIVESDecember 2023March 2025Abandon1510NoNo
18533062WOUND DRESSING BASED ON POLYMERIC MIXTURE OF CELLULOSE ACETATE AND HYALURONIC ACID EMBEDDED WITH COPPER OXIDE AND MAGNESIUM OXIDE NANOPARTICLESDecember 2023May 2025Abandon1830YesNo
18524148HYPERTONIC PHARMACEUTICAL COMPOSITIONS CONTAINING AN ANTI-PLATINUM CHEMOPROTECTANT AGENTNovember 2023April 2025Abandon1610NoNo
18517529PREPARATION OF SOLID CYCLODEXTRIN COMPLEXES FOR OPHTHALMIC ACTIVE PHARMACEUTICAL INGREDIENT DELIVERYNovember 2023October 2024Allow1110NoNo
18516052Solid Drug Tablets for Implantable Drug Delivery DevicesNovember 2023June 2025Allow1810NoNo
18511294SYNTHETIC ENAMEL AND USES THEREOFNovember 2023March 2025Allow1630NoNo
18511152METHOD OF MAKING SILVER NANOPARTICLES CAPPED WITH CARALLUMA SINAICA EXTRACT AND TREATMENT METHOD USING THE SAMENovember 2023December 2024Allow1320NoNo
18389181ANTIBIOTIC WITH SPIRULINA PLATENSIS AND PLANT EXTRACTSNovember 2023November 2024Abandon1220NoNo
18386906CRYSTALLINE FORM OF TRIETHYLENETETRAMINE TETRAHYDROCHLORIDE AND ITS PHARMACEUTICAL USENovember 2023March 2025Allow1620NoNo
18500595OPIOID FORMULATIONSNovember 2023July 2024Allow912NoNo
18500603OPIOID FORMULATIONSNovember 2023June 2025Abandon1920YesYes
18498542ANTI-ANDROGENS FOR THE TREATMENT OF METASTATIC CASTRATION-SENSITIVE PROSTATE CANCEROctober 2023January 2025Allow1520NoNo
18496417Altering Net Charge on Mannosylated Dextrans to Maximize Target Tissue Uptake and Off Target Competitive BlockingOctober 2023July 2024Allow810NoNo
18493090QUATERNARY AMMONIUM CYCLODEXTRIN AND PREPARATION METHOD AND USES THEREOF, AND SILVER NANOPARTICLE-CYCLODEXTRIN COMPLEX AND PREPARATION METHOD AND USES THEREOFOctober 2023December 2024Allow1421NoNo
18556634PURIFIED PSYCHOACTIVE ALKALOID EXTRACTION USING ACIDIFIED ACETONEOctober 2023May 2025Abandon1811NoNo
18381775COMPOSITIONS FOR ANTIHYPERTENSIVE DRUGSOctober 2023February 2025Abandon1631YesNo
18381351DISPENSER AND METHOD OF USE THEREOFOctober 2023October 2024Allow1100NoNo
18484334PHARMACEUTICAL COMPOSITIONOctober 2023November 2024Allow1310YesNo
18481549FORMULATIONS OF DAZUCORILANT, A GLUCOCORTICOID RECEPTOR MODULATOROctober 2023March 2025Allow1721YesNo
18476396METHOD FOR TREATING A BIOLOGICALLY CONTAMINATED SURFACESeptember 2023October 2024Allow1200YesNo
18476562BILAYER BIONIC DRUG-LOADED HYDROGEL, AND PREPARATION AND APPLICATION THEREOFSeptember 2023October 2024Abandon1220NoNo
18470182COMPOSITIONS AND METHODS FOR TREATING, PREVENTING OR REVERSING AGE ASSOCIATED INFLAMMATION AND DISORDERSSeptember 2023November 2024Allow1420NoNo
18460047INHIBITING ATAXIA TELANGIECTASIA AND RAD3-RELATED PROTEIN (ATR)September 2023December 2024Abandon1510NoNo
18238905Series of Skin-Whitening (Lightening) CompoundsAugust 2023October 2024Allow1310NoNo
18239072COMPOSITIONS AND METHODS FOR THE TREATMENT OF PRESBYOPIAAugust 2023October 2024Abandon1420NoNo
18237140BETA-LACTAM DERIVATIVES FOR THE TREATMENT OF DISEASESAugust 2023August 2024Allow1210NoNo
18450553LISINOPRIL FORMULATIONSAugust 2023January 2024Allow510NoNo
18233560EMULSIONS FOR TREATING MUCOUS MEMBRANE INFECTIONSAugust 2023April 2025Allow2011NoNo
18362789CATIONIC LIPIDS AND TRANSFECTION METHODSJuly 2023April 2025Allow2120NoNo
18358998SUBSTITUTED PYRIDINES AS DNMT1 INHIBITORSJuly 2023June 2024Allow1110NoNo
18356331CATHETER LOCK SOLUTION COMPRISING SODIUM CITRATE AND BENZYL ALCOHOLJuly 2023December 2024Allow1711NoNo
18357004USE OF DERIVATIVES CONTAINING C-O-P BONDS IN PATIENTS WITH KIDNEY FAILUREJuly 2023March 2025Abandon2011NoNo
18355360CONFORMAL COATING OF BIOLOGICAL SURFACESJuly 2023March 2025Allow2010NoNo
18222690BI-FUNCTIONAL CO-POLYMER USE FOR OPHTHALMIC AND OTHER TOPICAL AND LOCAL APPLICATIONSJuly 2023December 2024Allow1710NoNo
18221300MULTI-ARM POLYMER CONJUGATES OF TLR AGONIST COMPOUNDS AND RELATED IMMUNOTHERAPEUTIC TREATMENT METHODSJuly 2023September 2024Allow1510NoNo
18215257MINOCYCLINE COMPOUNDS FOR BIODEFENSEJune 2023January 2025Abandon1810NoNo
18341337MICROBIOTA SEQUENCE VARIANTS OF TUMOR-RELATED ANTIGENIC EPITOPESJune 2023April 2025Allow2210NoNo
18340702COMPOSITIONS AND METHODS FOR TOPICAL TREATMENT OF VASCULAR CONDITIONSJune 2023January 2025Abandon1931YesYes
18213022KAVA COMPOSITIONS AND METHODS OF USEJune 2023March 2025Allow2031YesYes
18211938NANOPARTICLE PROBES AND METHODS OF MAKING AND USE THEREOFJune 2023May 2025Allow2320NoNo
18338002METHODS OF DEPOSITING SILVER NANOSTRUCTURES ON TO IMPLANT SURFACESJune 2023December 2024Allow1810NoNo
18331093COMPOSITIONS, FORMULATIONS AND INTERLEUKIN PRODUCTION AND PURIFICATIONJune 2023March 2025Abandon2111NoNo
18201864ALPHA POLYGLUTAMATED PRALATREXATE AND USES THEREOFMay 2023September 2024Allow1610NoNo
18322417SINGLE- AND MIXED-METAL NANOPARTICLES, NANOPARTICLE CONJUGATES, DEVICES FOR MAKING NANOPARTICLES, AND RELATED METHODS OF USEMay 2023December 2024Allow1920NoNo
18315404METHODS OF TREATING HEMATOLOGICAL MALIGNANCIES USING 2-(2,6-DIOXOPIPERIDIN-3-YL)-4-((2-FLUORO-4-((3-MORPHOLINOAZETIDIN-1-YL)METHYL)BENZYL)AMINO)ISOINDOLINE-1,3-DIONMay 2023August 2024Allow1510NoNo
18315041CAPSID INHIBITORS FOR THE PREVENTION OF HIVMay 2023October 2024Abandon1710NoNo
18314442METHODS OF TREATING CHRONIC INFLAMMATORY DISEASESMay 2023July 2024Allow1410NoNo
18310706DRIFT REDUCTION ADJUVANT COMPOSITIONS AND METHODS OF USING SAMEMay 2023June 2024Allow1410YesNo
18310575SOLUTIONS FOR ORAL DOSAGEMay 2023January 2025Allow2021YesNo
18303530ORDER AND DISORDER AS A DESIGN PRINCIPLE FOR STIMULI-RESPONSIVE BIOPOLYMER NETWORKSApril 2023April 2025Allow2311NoNo
18134247METHODS AND COMPOSITIONS FOR SUSTAINED RELEASE MICROPARTICLES FOR OCULAR DRUG DELIVERYApril 2023November 2024Allow1910NoNo
18299444METHODS OF ALLEVIATING SYMPTOMS OF OCULAR SURFACE DISCOMFORT USING MEDICAL ICE SLURRYApril 2023November 2024Abandon1910NoNo
18133240CANNABINOID AND SUGAR ALCOHOL COMPLEX, METHODS TO MAKE AND USEApril 2023January 2025Abandon2101NoNo
182979743-(Hydroxy)-Pyridin-4(1H)-One Compounds and Methods of Making and Using the SameApril 2023February 2025Allow2220YesNo
18297134CARBOXYLIC ACID AROMATIC AMIDES AS ANTAGONISTS OF BRADYKININ B1 RECEPTORApril 2023October 2024Allow1920NoNo
18130706Antimicrobial ArticlesApril 2023April 2025Abandon2521NoNo
18130336NANOPARTICLE PHARMACEUTICAL DELIVERY SYSTEMApril 2023February 2025Allow2330NoNo
18129182METHODS OF DIAGNOSING AND TREATING DRY EYE SYNDROME AND COMPOSITIONS FOR TREATING A HUMAN EYEMarch 2023September 2024Allow1810NoNo
18188706METHOD FOR TREATING CANCERMarch 2023January 2025Abandon2210NoNo
18189010COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERSMarch 2023May 2025Allow2621NoNo
18124959GLUCOCORTICOID RECEPTOR MODULATORS TO TREAT PANCREATIC CANCERMarch 2023April 2025Allow2510NoNo
18187165OPHTHALMIC COMPOSITIONS AND METHODS FOR TREATING EYESMarch 2023May 2025Abandon2611NoNo
18026765SPECIALIZED PRO-RESOLVING MEDIATORS (SPMs) AS MELANOCYTE GROWTH PROMOTER AND PRO-SURVIVAL FACTORS AND USES THEREOFMarch 2023September 2024Allow1821NoNo
18184135METHODS OF ADMINISTERING AN ARIPIPRAZOLE INJECTABLE PREPARATIONMarch 2023December 2024Abandon2141YesNo
18121527TARGETING THE INNATE IMMUNE SYSTEM TO INDUCE LONG-TERM TOLERANCE AND TO RESOLVE MACROPHAGE ACCUMULATION IN ATHEROSCLEROSISMarch 2023February 2025Allow2320NoNo
18183415DISPENSING METHOD FOR PRODUCING DISSOLVABLE UNIT DOSE FILM CONSTRUCTSMarch 2023December 2024Allow2110NoNo
18117075METHODS OF TREATING CANCER WITH AN FGFR INHIBITORMarch 2023May 2024Allow1520NoNo
18176231DRIFT REDUCTION ADJUVANT COMPOSITIONS AND METHODS OF USING SAMEFebruary 2023June 2024Allow1520YesNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for art-unit 1614.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
77
Examiner Affirmed
48
(62.3%)
Examiner Reversed
29
(37.7%)
Reversal Percentile
73.1%
Higher than average

What This Means

With a 37.7% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is above the USPTO average, indicating that appeals have better success here than typical.

Strategic Value of Filing an Appeal

Total Appeal Filings
761
Allowed After Appeal Filing
178
(23.4%)
Not Allowed After Appeal Filing
583
(76.6%)
Filing Benefit Percentile
12.1%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 23.4% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.

Strategic Recommendations

✓ Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.

⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Art Unit 1614 - Prosecution Statistics Summary

Executive Summary

Art Unit 1614 is part of Group 1610 in Technology Center 1600. This art unit has examined 7,749 patent applications in our dataset, with an overall allowance rate of 48.7%. Applications typically reach final disposition in approximately 28 months.

Comparative Analysis

Art Unit 1614's allowance rate of 48.7% places it in the 6% percentile among all USPTO art units. This art unit has a significantly lower allowance rate than most art units at the USPTO.

Prosecution Patterns

Applications in Art Unit 1614 receive an average of 1.76 office actions before reaching final disposition (in the 43% percentile). The median prosecution time is 28 months (in the 53% percentile).

Strategic Considerations

When prosecuting applications in this art unit, consider the following:

  • The art unit's allowance rate suggests a more challenging examination environment compared to the USPTO average.
  • With fewer office actions than average, plan for relatively streamlined prosecution.
  • The median prosecution time is shorter than average and should be factored into your continuation and client communication strategies.
  • Review individual examiner statistics within this art unit to identify examiners with particularly favorable or challenging prosecution patterns.

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.